Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stem cells (MSCs) derived from bone marrow concentrate are being evaluated by Hospital Znojmo for their potential to enhance tendon-to-bone healing in patients undergoing reconstruction surgery for chronic rotator cuff tears, specifically supraspinatus muscle lesions. The therapy involves the application of concentrated autologous bone marrow-derived MSCs directly into the supraspinatus footprint during surgical repair. The mechanism of action relies on the regenerative, anti-inflammatory, and immunomodulatory properties of MSCs, which are hypothesized to improve the structural integrity and biological healing of the sutured tendon to the humerus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mesenchymal stem cells (Hospital Znojmo).